Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 31(15): 1975-80, 2013 Apr 08.
Article in English | MEDLINE | ID: mdl-23422141

ABSTRACT

Despite the widespread use of Bluetongue serotype 8 (BTV-8) vaccines across Europe, there remain unanswered questions on the effects of maternally derived antibodies (MDA) on vaccination. This study investigated the persistence of MDA in lambs and their interference on vaccine efficacy. Lambs born from hyperimmune ewes-i.e. ewes naturally infected with BTV-8 in 2007 and repeatedly vaccinated thereafter-were used. They were allocated to five groups (n=7/group), four receiving a BTV-8 vaccine at different ages (3, 5, 7 and 9 months) and one left unvaccinated. Vaccine protection was assessed upon a BTV-8 challenge performed at 10 months of age. The neutralising antibody titres were also measured throughout the study. Vaccination at 5, 7 and 9 months led to seroconversion and full clinical and virological protection in all animals. Among lambs vaccinated at 3 months, three (3/7) did not respond to vaccination and were not protected from challenge infection. Others animals (4/7) were fully protected from clinical disease and viraemia in accordance with their seropositive status at time of challenge. In our very stringent conditions, MDA hampered response to BTV-8 vaccination in lambs for at least 3 months after birth. Accordingly, the optimal age of vaccination needs to be adjusted to the immune status of the sheep population.


Subject(s)
Animals, Newborn/immunology , Bluetongue/immunology , Bluetongue/prevention & control , Colostrum/immunology , Sheep, Domestic/immunology , Vaccines, Inactivated/immunology , Viral Vaccines/immunology , Animals , Antibodies, Neutralizing/analysis , Antibodies, Neutralizing/immunology , Antibodies, Viral/analysis , Antibodies, Viral/immunology , Bluetongue/virology , Bluetongue virus/genetics , Bluetongue virus/immunology , Bluetongue virus/isolation & purification , Female , France , Pregnancy , RNA, Viral/analysis , Sheep, Domestic/virology , Time Factors , Vaccination/veterinary , Vaccines, Inactivated/administration & dosage , Viral Vaccines/administration & dosage
2.
Avian Dis ; 54(1 Suppl): 232-8, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20521637

ABSTRACT

Fowlpox (FP)-vectored avian influenza (FP-AI) vaccines are used in 1-day-old chickens, but they have also recently been shown to be immunogenic in ducks. The objectives of this work were 1) to evaluate safety and to compare the immunogenicity in ducks of three poxvirus vectors (fowlpox, canarypox, and vaccinia) expressing the same hemagglutinin gene from an H5N1 isolate, 2) to study the effect of the dose of the FP-AI and the presence of an adjuvant in 1-day-old Pekin ducks on antibody response after a boost with inactivated vaccine given 3 wk later, and 3) to confirm the immunogenicity of such a heterologous prime-boost vaccination scheme in 1-day-old Muscovy ducks. Immunogenicity induced by the three poxvirus vectors was comparable, and the FP vector was selected for the other studies. As published previously, there was a strong dose effect of the FP-AI priming on the hemagglutination inhibition (HI) titers induced after the boost with an inactivated vaccine. In contrast, the two tested adjuvants did not significantly increase the activity of FP-AI priming. The heterologous prime-boost regimen given to both Muscovy and Pekin ducklings at 1 and 14 or 21 days of age, respectively, was shown to be at least as immunogenic as two administrations of inactivated vaccines given at 2 and 5 wk of age. However, HI antibody titers were of short duration for both vaccine schemes, and their persistence was heterogeneous among individual birds.


Subject(s)
Avipoxvirus , Ducks/genetics , Influenza Vaccines/immunology , Influenza in Birds/prevention & control , Animals , Drug Administration Schedule , Female , Influenza A Virus, H5N1 Subtype/immunology , Influenza Vaccines/administration & dosage , Time Factors , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...